ICATIBANT WKT (Wockhardt Bio Pty Ltd)
Product name
ICATIBANT WKT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
124 (255 working days)
Active ingredients
icatibant acetate
Registration type
New generic medicine
Indication
[TRADE NAME] is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older with C1-esterase-inhibitor deficiency.